Tag: IPO

4 articles

Market Moves

China BCI funding and IPO tracker 2026

The 2026 financing rounds and listing steps by Chinese brain-computer interface companies verified by InsideBCI, from BrainCo's RMB 2 billion round to Neuracle's STAR Market application, with amounts, lead investors and sources. Updated as new rounds are announced.

Nov 8

Market Moves

Three Chinese BCI companies raised RMB 1.66 billion in eight days

NeuroXess, Nanochap and Shanghai's Zhudong Technology announced rounds totalling RMB 1.664 billion between 28 October and 4 November 2026, with state-backed funds among the investors, while StairMed filed for A-share pre-listing tutoring. The 'over RMB 3 billion in a week' figure in Chinese coverage adds StairMed's financing since July.

Nov 5

Market Moves

Neuracle has sold 13 brain implants at a listed RMB 475,000 each since July

Neuracle Technology (Shanghai) (博睿康), maker of China's first approved invasive brain-computer interface, has sold 13 NEO-ONE SCI implant systems and implanted 8 since its first commercial sale in July 2026, with more than 70 more in firm and intended orders. The system is listed at RMB 475,000 per set on procurement platforms in 27 provinces and is not covered by any basic medical insurance catalogue. Neuracle made the figures public on 29 September 2026 in its answers to the Shanghai Stock Exchange's first round of questions on its STAR Market listing application, 110 days after the application was accepted. First-half 2026 revenue was RMB 46.3 million, almost all from its non-invasive business and none from the implant, with a net loss of RMB 65.5 million. No listing committee meeting has been scheduled. None of the best-known Western developers of implanted BCIs, Neuralink, Synchron, Precision Neuroscience, Paradromics and Blackrock Neurotech, is publicly listed.

Oct 1